Tao Liang | Cell Death Pathway | Best Researcher Award

Published on by Cell Biologist

Mr. Tao Liang | Cell Death Pathway | Best Researcher Award

Mr. Tao Liang, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China

Dr. Tao Liang is an accomplished medicinal chemist with deep expertise in small molecule drug design, synthesis, and pharmacological evaluation. Originating from Dancheng County, Henan Province, and currently residing in Wuhu City, Anhui Province, Dr. Liang is an Assistant Researcher at The Second Affiliated Hospital of Wannan Medical College. He earned his Doctor of Medicine from Shandong University, a leading institution under China’s “Double First-Class” initiative. With over 7 first-author SCI publications and multiple national invention patents, his research significantly contributes to targeted cancer therapies, especially involving HDAC6-selective inhibitors and Bax agonists. He has successfully led key projects funded by the Anhui Provincial Government and participated in prestigious National Natural Science Foundation of China projects. Known for both scientific depth and innovation, Dr. Liang has been recognized with national-level scholarships and university-wide honors for outstanding research achievements and academic excellence.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. High-Impact Publications

    • Authored 7 first-author SCI papers, including publications in top-tier journals like Acta Pharm Sin B (IF 14.907) and J Med Chem (IF 8.039).

    • Published extensively on HDAC6 isoform-selective inhibitors and apoptosis-targeting small molecules, a niche and cutting-edge domain in anticancer drug research.

  2. Research Leadership & Innovation

    • Serves as Principal Investigator for two key provincial research projects focusing on selective cancer therapies.

    • Demonstrated innovation in designing dual-target inhibitors (MMP/HDAC) and novel Bax agonists.

  3. National-Level Collaborations

    • Participated in major National Natural Science Foundation of China projects (5 total), totaling over RMB 2 million in funding.

    • Engaged with multidisciplinary teams and key opinion leaders, including renowned researchers such as Prof. Hao Fang and Prof. Xuben Hou.

  4. Academic Recognition

    • Winner of prestigious honors such as the National Scholarship, Outstanding Doctoral Graduate, and guest speaker at elite academic forums.

    • Recipient of 15+ national and university-level awards, including innovation prizes and scholarships.

  5. Patent Contributions

    • Holds 4 national invention patents, reflecting translational potential and real-world application of his research outputs.

🔧 Areas for Improvement:

  1. International Visibility & Collaboration

    • Current research impact is primarily within domestic circles (China). Engaging in cc, postdoctoral exchanges, or publishing with international co-authors would elevate recognition.

  2. Clinical Translation Pipeline

    • Despite strong preclinical development, there is no direct evidence of transition to clinical trials or industrial commercialization. Partnering with biotech/pharma could increase translational outcomes.

  3. Leadership Beyond Research

    • As an early-career researcher, administrative leadership (e.g., lab director, national committee memberships) may still be developing. Building a research group or mentoring PhD students would strengthen this.

  4. Interdisciplinary Expansion

    • Expertise is strong in medicinal chemistry, but cross-disciplinary projects involving AI/drug discovery, systems biology, or clinical oncology could broaden the impact.

🎓 Education:

Dr. Tao Liang received his Bachelor of Science in Pharmacy from Shandong University (2013.9–2017.6), one of China’s elite institutions under the National “985 Project” and “Double First-Class” initiative. Continuing at the same university, he pursued a Master’s and Ph.D. in Medicinal Chemistry, earning a Doctor of Medicine degree in 2022. Shandong University, renowned for its Ministry of Education Class A-rated disciplines, provided Dr. Liang with a rigorous scientific environment and access to state-of-the-art research facilities. During his academic training, he developed a strong foundation in chemical biology, natural product synthesis, and drug development. His educational journey has been marked by consistent excellence, earning him accolades like National Scholarships and Outstanding Graduate awards. His academic credentials and extensive research during his Ph.D. have positioned him as a leading young researcher in the field of medicinal chemistry in China.

💼 Work Experience:

Since August 2022, Dr. Tao Liang has been serving as an Assistant Researcher at The Second Affiliated Hospital of Wannan Medical College. His research focuses on the structural design, chemical synthesis, and pharmacological activity evaluation of small molecule drugs, particularly targeting HDAC isoforms and apoptotic regulators like Bax. He currently leads two key projects: one on HDAC6-selective inhibitors and another on Bax agonists for cervical cancer therapy, funded by the Anhui Provincial Higher Education and Health Commission respectively. Previously, he participated in several high-impact national research projects, including two funded by the National Natural Science Foundation of China, focusing on anti-cancer drug discovery. His roles have involved both independent project leadership and critical collaboration within multidisciplinary teams. Dr. Liang’s work experience showcases his capabilities in translational medicinal chemistry research and positions him as a promising talent in pharmaceutical innovation.

🏆 Awards and Honors:

Dr. Tao Liang has received more than a dozen honors for his outstanding academic and research contributions. These include the prestigious National Scholarship (2021), Outstanding Doctoral Graduate of Shandong University (2022), and multiple first-class scholarships throughout his postgraduate studies. He was a special guest speaker at prominent forums like the “Haiyou Doctoral Forum” and “Lao Xu Talks about High Strategies.” His undergraduate years were equally distinguished, earning the first prize in the ‘Challenge Cup’ and honors like “Outstanding Graduate” and “Excellent Communist Youth League Member”. His early career was also decorated with international recognitions such as the First Prize for Innovation Results at the World University Students’ Pharmaceutical Garden Forum. These awards highlight both his academic brilliance and commitment to scientific advancement, affirming his eligibility and strength as a nominee for the Best Researcher Award.

🔬 Research Focus:

Dr. Tao Liang’s research centers on the design, synthesis, and biological evaluation of small molecule inhibitors with a primary focus on histone deacetylase 6 (HDAC6) isoform-selective inhibitors and Bax agonists for cancer therapy. His work integrates computational modeling, medicinal chemistry, and pharmacodynamics to create targeted therapies aimed at epigenetic modulation and apoptosis induction in cancer cells. He has actively contributed to national-level projects exploring dual-target inhibitors (MMP/HDAC) and small molecule interventions for Mcl-1 and striatal enriched tyrosine phosphatase (STEP) targets. Dr. Liang is particularly recognized for his innovation in optimizing chemical scaffolds for selective inhibition and minimizing off-target effects. Through collaborative and independent research, he aims to address challenges in chemotherapeutic resistance and toxicity. His scientific pursuits align with current global trends in precision oncology, making significant strides in targeted therapy development and laying a foundation for future clinical translation.

📚 Publications Top Notes:

  1. 📘 Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor – Bioorganic Chemistry, 2025

  2. 📗 Targeting histone deacetylases for cancer therapy: Trends and challenges – Acta Pharmaceutica Sinica B, 2023

  3. 📙 Potential applications of BPFP1 in Bcl-2 protein quantification, carcinoma cell visualization, cell sorting and early cancer diagnosis – European Journal of Medicinal Chemistry, 2021

  4. 📕 Design, synthesis and biological evaluation of 3,4-disubstituted-imidazolidine-2,5-dione derivatives as HDAC6 selective inhibitors – European Journal of Medicinal Chemistry, 2021

  5. 📘 Recent Development of Novel HDAC6 Isoform-selective Inhibitors – Current Medicinal Chemistry, 2021

  6. 📗 HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells – Journal of Medicinal Chemistry, 2020

  7. 📙 Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors – ACS Medicinal Chemistry Letters, 2019

  8. 📕 Synthesis and Antiproliferative Activity of Thiadiazole Peptidomimetic Derivatives – Chinese Journal of Organic Chemistry, 2016

🧾 Conclusion:

Dr. Tao Liang is highly suitable for the Best Researcher Award, especially in the early- to mid-career researcher category. His extensive publication record, innovative medicinal chemistry work, leadership in funded projects, and impressive academic recognitions make him an exemplary candidate.

minghe luo | Microbial Cell Biology | Best Researcher Award

Published on by Cell Biologist

Mr. minghe luo | Microbial Cell Biology | Best Researcher Award

Mr. minghe luo , Chongqing University of Technology , China

Dr. Minghe Luo, born in April 1984, is an accomplished pharmaceutical scientist and Associate Professor at Chongqing University of Technology. Specializing in natural product biosynthesis, he has made significant contributions to the discovery of novel antibiotics and the mechanistic understanding of biosynthetic pathways from marine microorganisms. His academic journey has taken him through respected institutions including Wuhan University and Southwest University, with extensive research training at the South China Sea Institute of Oceanology. Known for his collaborative spirit and deep expertise in medicinal chemistry, Dr. Luo has authored numerous impactful publications in journals like Angewandte Chemie and Organic Letters. His work not only advances scientific knowledge but also offers practical implications for antibiotic development. A dedicated educator and researcher, Dr. Luo continues to explore microbial biosynthetic machinery, aiming to discover new therapeutics for drug-resistant infections.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Depth of Expertise:
    Dr. Luo has solid academic foundations with a PhD in Pharmacy and a Master’s in Medicinal Chemistry of Natural Products. His specialty in natural products biosynthesis—particularly from marine microorganisms—positions him uniquely in pharmaceutical research.

  2. Research Output & Impact:
    He has authored over 15 research papers in high-impact journals such as Angewandte Chemie, Organic Letters, Chemical Engineering Journal, and Journal of Natural Products. His work tackles urgent global needs, like antibiotic resistance, with research on compounds targeting MRSA and other drug-resistant pathogens.

  3. Innovation in Biosynthesis:
    His research on trans-AT polyketide synthases, novel biosynthetic pathways, and genome mining for cryptic natural products exemplifies forward-thinking, interdisciplinary science.

  4. Independent Research and Teaching:
    As an Associate Professor, he leads independent projects while teaching and mentoring students—demonstrating both leadership and academic service.

  5. Collaboration:
    His co-authored papers reflect strong collaborative ties, including with international researchers like Prof. Jeroen Dickschat (Germany), a mark of scientific credibility and connectivity.

⚠️ Areas for Improvement:

  1. Patent/Translational Outputs:
    While his publications are excellent, showcasing patents, industry collaborations, or drug development pipelines would better demonstrate translational relevance.

  2. Global Outreach:
    Participation in international conferences, scientific boards, or as an editorial reviewer could enhance his global visibility.

  3. Public Engagement:
    Greater involvement in public science communication or outreach could boost his societal impact profile.

🎓 Education:

Dr. Minghe Luo earned his Doctorate in Pharmacy from Wuhan University (2018–2021), under the supervision of Prof. Yuhui Sun, focusing on the biosynthesis of natural products. Prior to this, he completed a Master’s degree in Medicinal Chemistry of Natural Products through a joint program between Southwest University and the South China Sea Institute of Oceanology (2008–2011), guided by Professors Zichuan Bai and Jianhua Ju. His postgraduate training emphasized the chemical characterization and bioactivity of marine-derived fungal metabolites. This unique blend of pharmacy and chemistry, alongside rigorous experimental research, laid the foundation for his expertise in microbial natural product discovery and biosynthesis. Dr. Luo’s academic development reflects a deep commitment to both theoretical understanding and applied research, equipping him with the tools to lead investigations into novel bioactive compounds, particularly those from extreme marine environments.

💼 Experience:

Dr. Luo began his career as a research scientist at the Third Affiliated Hospital of the Third Military Medical University (2011–2018), focusing on microbial natural product discovery. In 2021, he joined Chongqing University of Technology as an Associate Professor, where he leads independent projects on biosynthetic pathway elucidation and engineering of marine microbial metabolites. His role includes teaching pharmacy courses and mentoring graduate students. Dr. Luo’s experience spans isolation, structural elucidation, and genetic manipulation of microbial strains to unlock cryptic biosynthetic potential. His consistent publication record demonstrates both foundational research and innovative biosynthetic strategies. Over the years, he has cultivated a reputation for high-quality research and collaborative spirit, contributing significantly to antibiotic and anticancer compound discovery pipelines. He is particularly recognized for exploring deep-sea actinomycetes, making meaningful strides in developing novel antibacterial agents against drug-resistant pathogens.

🔬 Research Focus:

Dr. Luo’s research centers on the biosynthesis of microbial natural products, particularly from marine-derived actinomycetes and fungi. His primary interests include identifying novel polyketides, non-ribosomal peptides, and hybrid metabolites with antibacterial or anticancer potential. He employs genome mining, biosynthetic gene cluster (BGC) characterization, and pathway engineering to discover and optimize the production of bioactive compounds. A key theme in his work is understanding the mechanisms of tailoring enzymes (e.g., methyltransferases, P450s, dehydrating modules) that diversify natural product structures. Dr. Luo has also made major strides in elucidating biosynthetic pathways like those for hangtaimycin and streptovaricins. He is passionate about translating his findings into new drug leads, particularly targeting MRSA and multi-drug-resistant infections. His interdisciplinary approach bridges organic chemistry, synthetic biology, and pharmacology, contributing to the broader field of drug discovery from marine natural sources.

📚 Publications Top Notes:

  1. 🧪 The mechanism of dehydrating bimodules in trans-AT polyketide biosynthesis: hangtaimycin study – Angew. Chem. Int. Edit.

  2. 🧬 Methylation in hangtaimycin biosynthesis and its antibacterial activities – Synth. Syst. Biotechnol.

  3. 💊 Local delivery of deep marine equisetin via PVP nanofibers for anti-MRSA – Chem. Eng. J.

  4. 🌊 Natural siderophore acremonpeptides and their aluminum complex from Acremonium – J. Nat. Prod.

  5. 🔬 Amino acid-conjugated anthraquinones from marine Penicillium sp. – J. Nat. Prod.

  6. 🌐 Halogenated anthraquinones from Aspergillus sp. – J. Nat. Prod.

  7. 🧫 Genome-based mining of carpatamides I–M and their biosynthetic gene cluster – Mar. Drugs

  8. 🌿 Antibacterial lobophorin L and M from marine Streptomyces sp. – Nat. Prod. Res.

  9. 🧪 Two new streptovaricin derivatives from Streptomyces spectabilis mutants – Nat. Prod. Res.

  10. ⚗️ Mycophenolic acid derivative from Penicillium sp. fermentation – Nat. Prod. Res.

🧾 Conclusion:

Dr. Minghe Luo clearly exhibits the scientific rigor, innovation, and productivity deserving of the Best Researcher Award. His contributions to the field of natural product chemistry and biosynthesis, especially in the context of antimicrobial resistance, are both timely and impactful. With minor improvements in translational output and international visibility, he is poised to become a leading figure globally in pharmaceutical biotechnology.

Xingting Guo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Xingting Guo | Stem Cell Research | Best Researcher Award

Assist. Prof. Dr. Xingting Guo , Peking University Third Hospital , China

Dr. Xingting Guo is a dedicated postdoctoral fellow at the National Institute of Biological Sciences (NIBS), Beijing, where she has been working since 2018. With a strong academic foundation in biochemistry and molecular biology, her research delves into stem cell biology, cellular differentiation, and tumorigenesis using Drosophila and mouse models. Her expertise lies in integrating genetics, biochemistry, single-cell sequencing, and bioinformatics to unravel mechanisms of cell fate specification and intestinal homeostasis. Dr. Guo has co-authored several high-impact publications and has presented her research at both national and international conferences. Her contributions have significantly advanced our understanding of enteroendocrine cells (EECs), tissue identity, and inter-organ communication. Passionate and detail-oriented, she is actively contributing to biomedical sciences with a vision to translate fundamental biology into therapeutic insights. Her work is paving the way for novel treatments for metabolic diseases and cancers.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Innovative Research Focus: Dr. Guo has made pioneering contributions in stem cell biology, particularly in understanding cell fate specification, enteroendocrine diversity, and tumor suppression using Drosophila and murine models.

  2. Multidisciplinary Skillset: She integrates genetics, high-throughput sequencing, bioinformatics, organoid culture, and in vivo models, showcasing deep technical expertise.

  3. High-Impact Publications: Co-first author in multiple peer-reviewed journals, including Cell Reports, Nature Communications, and FEBS Journal.

  4. Leadership in Research: From graduate researcher to postdoctoral fellow, she has led multiple independent projects, contributing novel findings to developmental and regenerative biology.

  5. International Recognition: Regular presenter at top-tier conferences globally, including the European Drosophila Research Conference and Annual Drosophila Research Conference (USA).

  6. Research Funding: Successfully secured National Natural Science Foundation of China funding, reflecting scientific merit and recognition.

🔍 Areas for Improvement:

  1. Broader Collaboration: Expanding collaborations outside her current institute or internationally may enhance the translational reach and impact of her research.

  2. Mentorship Roles: While her research is strong, formal mentorship roles (e.g., supervising Ph.D. students) or teaching contributions could further demonstrate leadership.

  3. Clinical Translation: Though her mouse model work touches on therapeutic discovery, publishing more translational or clinical-facing studies could boost her impact in applied biomedical research.

🎓 Education:

Dr. Xingting Guo earned her Ph.D. in Biochemistry and Molecular Biology from the College of Life Sciences at Beijing Normal University (2012–2018), where she began her in-depth research on stem cell biology and tissue differentiation in Drosophila. Prior to this, she completed her Bachelor’s degree in Biological Engineering at Nanjing Agricultural University (2008–2012), where she was honored with multiple scholarships for academic excellence. Throughout her education, she developed a robust foundation in molecular biology, genetics, and developmental biology, equipping her with the skills to tackle complex biological questions. Her academic journey has been characterized by continuous academic excellence, curiosity-driven research, and a commitment to uncovering the molecular mechanisms of health and disease. Her education laid the groundwork for her successful transition to cutting-edge postdoctoral research in developmental biology and regenerative medicine.

💼 Experience:

Dr. Guo began her research career at NIBS Beijing as a graduate student in 2012, transitioning into a postdoctoral fellow in 2018 under the mentorship of Dr. Rongwen Xi. Her research primarily uses Drosophila intestinal systems and murine models to explore the regulation of cellular identity, differentiation, and plasticity. She has led multiple projects on tumor suppression, transcriptional regulation, and enteroendocrine diversity using advanced techniques like genetic manipulation, single-cell RNA sequencing, and organoid cultures. Additionally, she contributes to translational research by identifying drug targets for diabetes-related therapy by reprogramming intestinal cells into insulin-producing β-cells. Her interdisciplinary approach and long-standing expertise in stem cell biology highlight her versatility and innovation in research. Her consistent progression from graduate student to independent researcher reflects her strong scientific rigor and leadership in high-impact studies.

🏆 Awards and Honors:

Dr. Xingting Guo has been recognized for her academic excellence and scientific contributions through numerous honors. During her Ph.D., she was awarded the First Class Academic Scholarship for two consecutive years (2014–2016). As an undergraduate, she earned the prestigious Cyrus Tang Scholarship four times, along with the First Class Scholarship at Nanjing Agricultural University. In recent years, she has taken on the role of a peer reviewer for Bio-protocols, highlighting her engagement with the scientific community. Dr. Guo’s research excellence has led her to represent her work at top-tier conferences, including the Annual Drosophila Research Conference (USA) and the European Drosophila Research Conference (Switzerland). Her contributions were also supported by a grant from the National Natural Science Foundation of China (Grant No. 3210050518), demonstrating her ability to secure competitive funding. These accolades mark her as a rising star in molecular and developmental biology.

🔬 Research Focus:

Dr. Guo’s research focuses on the molecular regulation of stem cell differentiation, cellular identity maintenance, and neuroendocrine cell plasticity using Drosophila and mouse models. She investigates how transcription factors such as ttk69 influence enteroendocrine (EEC) specification, tissue homeostasis, and tumor suppression. Using cutting-edge tools like CRISPR, single-cell transcriptomics, and in vivo lineage tracing, she deciphers how intestinal stem cells differentiate into diverse terminal cell types. Her recent work explores how intestinal EECs regulate systemic physiology via neuropeptides in response to environmental cues like starvation and mating. In parallel, she studies cell-fate reprogramming in mammals to identify potential therapeutic strategies for diabetes by inducing insulin-producing cells in the gut. By bridging basic biology with translational goals, her work contributes to regenerative medicine, oncology, and metabolic disease research.

📚 Publications Top Notes:

  • 🧠 Cell-fate conversion of intestinal cells in adult Drosophila midgut by depleting a single transcription factor, Nature Communications, 2024

  • 🔍 The Specification and Function of Enteroendocrine Cells in Drosophila and Mammals: A Comparative Review, FEBS Journal, 2021

  • 🧬 A Switch in Tissue Stem Cell Identity Causes Neuroendocrine Tumors in Drosophila Gut, Cell Reports, 2020

  • 🧫 The Cellular Diversity and Transcription Factor Code of Drosophila Enteroendocrine Cells, Cell Reports, 2019

  • 🧬 Division of Labor: Roles of Groucho and CtBP in Notch-Mediated Lateral Inhibition, Stem Cell Reports, 2019

  • 📘 Signaling Pathways Regulating Stem Cells, Book Chapter, Springer, 2015

  • 🛑 Ttk69 acts as a master repressor of enteroendocrine cell specification, Development, 2015

  • 🧪 EGFR and Notch signaling regulate gastric stem cells, Cell Research, 2014

  • 🧠 Sox9 Ortholog Regulates Intestinal Homeostasis and Regeneration in Drosophila, Cell Reports, 2020

🧾 Conclusion:

Dr. Xingting Guo is a highly qualified and deserving candidate for the Best Researcher Award. Her exceptional track record in stem cell biology, cellular reprogramming, and disease modeling makes her a rising star in the life sciences. With a unique combination of technical excellence, scientific innovation, and publication strength, she has already made a significant impact on our understanding of intestinal cell biology and endocrine regulation. Addressing a few career development aspects—like expanding collaborative networks and clinical translation—will make her an even more formidable leader in the field. Given her achievements, potential, and contributions, she is strongly recommended for this prestigious honor.